{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:59:06Z","timestamp":1787885946007,"version":"build-2784847793"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Epidemiological studies of statin use and liver cancer risk have produced conflicting results. We examined the association between statin use and risk of primary liver cancer in two large independent study populations taking account of important covariates and main indications of statins such as high cholesterol and chronic liver disease. We performed a nested case\u2013control study within the Scottish Primary Care Clinical Informatics Unit (PCCIU) database. Five controls were matched to cases with primary liver cancer and we used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with statin use. We also conducted a prospective cohort study within the UK Biobank using self\u2010reported statin use and cancer\u2010registry recorded primary liver cancer outcomes. Cox regression was used to calculate hazard ratios (HRs) and 95% CIs. In the PCCIU case\u2013control analysis, 434 liver cancer cases were matched to 2,103 controls. In the UK Biobank cohort, 182 out of 475,768 participants developed incident liver cancer. Statin use was associated with 39% lower risk of liver cancer in the PCCIU (adjusted OR 0.61, 95% CI 0.43\u20130.87). When we examined specific subtypes of liver cancer in the UK Biobank, statin use was associated with lower risk of hepatocellular carcinoma (HCC; adjusted HR, 0.48; 95% CI, 0.24\u20130.94) but not intrahepatic bile duct carcinoma (IBDC; adjusted HR, 1.09; 95% CI, 0.45\u20132.64). In conclusion, we found a consistent inverse relationship between statin use and risk of primary liver cancer which was only seen for HCC but not IBDC.<\/jats:p>","DOI":"10.1002\/ijc.32426","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T18:13:51Z","timestamp":1558462431000},"page":"1250-1260","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Statin use and risk of liver cancer: Evidence from two population\u2010based studies"],"prefix":"10.1002","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-6643","authenticated-orcid":false,"given":"Kim Tu","family":"Tran","sequence":"first","affiliation":[{"name":"Cancer Epidemiology and Health Services Research Group, Centre for Public Health Queen's University Belfast  Belfast Northern Ireland United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-8893","authenticated-orcid":false,"given":"\u00dana C.","family":"McMenamin","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology and Health Services Research Group, Centre for Public Health Queen's University Belfast  Belfast Northern Ireland United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen G.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology and Health Services Research Group, Centre for Public Health Queen's University Belfast  Belfast Northern Ireland United Kingdom"},{"name":"Centre for Cancer Research and Cell Biology Queen's University Belfast  Belfast Northern Ireland United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R.","family":"Cardwell","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology and Health Services Research Group, Centre for Public Health Queen's University Belfast  Belfast Northern Ireland United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Murchie","sequence":"additional","affiliation":[{"name":"Academic Primary Care, Institute of Applied Health Sciences University of Aberdeen  Aberdeen United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Iversen","sequence":"additional","affiliation":[{"name":"Academic Primary Care, Institute of Applied Health Sciences University of Aberdeen  Aberdeen United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Statistics Team, Institute of Applied Health Sciences University of Aberdeen  Aberdeen United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-5308","authenticated-orcid":false,"given":"Aaron P.","family":"Thrift","sequence":"additional","affiliation":[{"name":"Section of Epidemiology and Population Sciences Department of Medicine, Baylor College of Medicine  Houston TX"},{"name":"Dan L Duncan Comprehensive Cancer Center Baylor College of Medicine  Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.11.020"},{"key":"e_1_2_7_3_1","volume-title":"Trends in Liver Cancer Mortality Among Adults Aged 25 and Over in the United States, 2000\u20132016. NCHS Data Brief, no 314","author":"Xu J","year":"2018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i6.1544"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep45846"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.013"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.304"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.09.007"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0252-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317504"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007435"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.10.005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e328358761a"},{"key":"e_1_2_7_15_1","unstructured":"University of Aberdeen The Institute of Applied Health Sciences. Primary Care Clinical Informatics Unit Research. Available from:https:\/\/www.abdn.ac.uk\/iahs\/research\/primary-care\/pcciur\/index.php[cited May 3 2018]."},{"key":"e_1_2_7_16_1","unstructured":"Scottish Clinical Information Management in Practice. SCIMP Guide to Read Codes Read Version 2 5 byte. Available from:https:\/\/www.scimp.scot.nhs.uk\/better-information\/clinical-coding\/scimp-guide-to-read-codes[cited January 17 2019]."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4145"},{"key":"e_1_2_7_18_1","volume-title":"British National Formulary","author":"British Medical Association, Royal Pharmaceutical Society","year":"2010"},{"key":"e_1_2_7_19_1","unstructured":"World Health Organisation. World Health Organisation Collaborating Centre for Drug Statistics and Methodology. Available from:http:\/\/www.who.int\/medicines\/regulation\/medicines-safety\/toolkit_ddd\/en\/[cited May 12 2018]."},{"key":"e_1_2_7_20_1","volume-title":"Scottish Index of Multiple Deprivation 2009: General Report","author":"Donnelly R","year":"2009"},{"key":"e_1_2_7_21_1","unstructured":"UK Biobank. About UK Biobank. Available from:http:\/\/www.ukbiobank.ac.uk\/about-biobank-uk\/[cited February 2 2018]."},{"key":"e_1_2_7_22_1","first-page":"314","volume-title":"Health and deprivation: inequality and the north","author":"Whitelegg J","year":"1988"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep26256"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7832"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26338"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw109"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12641"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1751"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc0602.103393"},{"key":"e_1_2_7_33_1","first-page":"1105","article-title":"Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation","volume":"30","author":"B\u00f6rkhem\u2010Bergman L","year":"2010","journal-title":"Anticancer Res"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.5200"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29172"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27157"},{"key":"e_1_2_7_37_1","unstructured":"The Food and Drug Administration. LIPITOR\u00ae (atorvastatin calcium). Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020702s056lbl.pdf[cited December 12 2018]."},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1267"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-018-1058-4"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4154"},{"key":"e_1_2_7_41_1","first-page":"105","article-title":"Role of non\u2010selective Beta blockers in hepatocellular carcinoma: an analysis in patients with cirrhosis and portal hypertension","volume":"8","author":"Patel H","year":"2015","journal-title":"North Am J Med Sci"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14796"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146272"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.32426","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T23:34:27Z","timestamp":1694043267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.32426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1002\/ijc.32426"],"URL":"https:\/\/doi.org\/10.1002\/ijc.32426","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"2019-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}